Bone News and Research

RSS

FDA clears Biomet's Active Articulation Hip System

Biomet, Inc., a global leader in the manufacture of orthopedic and biotechnology products, today announced clearance of its Active Articulation E1 Dual Mobility Hip System, by the United States Food and Drug Administration.

27 Apr 2011

Vexim's SpineJack implant obtains ISO certification in Canada

Vexim, the specialist in medical devices for the minimally invasive, anatomical treatment of vertebral compression fractures, today announced that it has obtained CAN/CSA ISO 13485:2003 certification in Canada.

26 Apr 2011

SI-BONE receives FDA approval for updated iFuse Implant System

SI-BONE, Inc., a medical device company that is pioneering the use of a minimally invasive surgical device to treat the sacroiliac joint announced the U.S. Food and Drug Administration approved a major modification to the existing product label.

26 Apr 2011

Epic Imaging receives 100% Mammography Quality Standards Act score

Epic Imaging recently received a 100 percent score on its yearly American College of Radiology Mammography Quality Standards Act inspection.

25 Apr 2011

Early meniscus interventions may help prevent future osteoarthritis

Aging often means bad knees, and bad knees often mean osteoarthritis, a common and painful disability that affects more than 20 million Americans.

25 Apr 2011

Medtronic's English Channel swimming competition to raise awareness on ALS

In August 2011, Doug McConnell of Barrington, Illinois, expects to be the 48th person over age 50 to successfully swim across the English Channel. He will be swimming more than 21 grueling miles in memory of his father, David, who passed away from ALS.

From Medtronic 25 Apr 2011

Roswell Park Cancer Institute named Blue Distinction Center for Transplants

Roswell Park Cancer Institute (RPCI) has been named a Blue Distinction Center for Transplants® by BlueCross BlueShield of Western New York for demonstrating better overall quality of care and patient results in bone marrow/stem cell (autologous and allogeneic) procedures.

22 Apr 2011

Fiber-reinforced composite material holds promise for oral applications and orthopedics

New materials and new technologies offer opportunities to bring implant dentistry to more patients. Fiber-reinforced composite is a new material that promises advantages for use in oral and craniofacial applications as well as in orthopedics. Discovering how it responds to stress and strain can help gauge its usefulness.

22 Apr 2011

Study identifies major osteoporosis knowledge gaps for some patient groups

A fracture in a person over the age of 50 can be a sign of osteoporosis, yet some patient populations have little knowledge of the disease. According to a groundbreaking study published in a recent Journal of Bone and Joint Surgery (JBJS), male and non-English speaking patients tend to have the least knowledge of osteoporosis, putting them at high risk for a subsequent fracture.

22 Apr 2011

DEKRA, Health Canada clear ORTHOCON's new Absorbable Bone Hemostat Matrix

ORTHOCON, Inc., a privately-held therapeutic device company, today announced that DEKRA and Health Canada have cleared its HEMASORB Absorbable Bone Hemostat Matrix for clinical use and sale in Europe and Canada.

22 Apr 2011

Misonix enters new three year distribution agreement with Instrumentacion

Misonix, Inc., a medical device company that designs, manufactures, and markets innovative, therapeutic, ultrasonic products worldwide for wound debridement, spinal surgery, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications, has entered into a new, three year, exclusive distribution agreement with Instrumentacion, S.A. based in Bogota, Colombia.

22 Apr 2011

EPO doping drug can reduce cerebral malaria related deaths

Almost 3.3 billion people, half of the world's population, risk being infected with malaria. Despite having effective means against malaria, the WHO reports 250 million cases of malaria each year and more than 700,000 related deaths. Researchers at the University of Copenhagen have now discovered that EPO, the doping drug known from professional cycling, can significantly reduce cerebral malaria related deaths.

22 Apr 2011

First implantation of blended vitamin E total knee replacement in the U.S

DJO Global, Inc., a leading provider of medical device solutions for musculoskeletal health, vascular health and pain management, today announced the implantation of the first blended vitamin E total knee replacement in the U.S.

21 Apr 2011

Astra Tech OsseoSpeed TX Profile implants now include Atlantis Abutments

Astra Tech expands their patient-specific abutment solution for North American customers, to now include Atlantis™ Abutments for Astra Tech OsseoSpeed™ TX Profile implants.

21 Apr 2011

Stanford and SanBio initiate SB623 Phase 1/2a clinical trial for stroke disability

The Stanford University School of Medicine and SanBio Inc. today announced the initiation of a Phase 1/2a clinical trial testing the safety and efficacy of a novel allogeneic cell therapy product, SB623, on patients suffering from stable deficits resulting from previous stroke injuries.

21 Apr 2011

Harvest initiates enrollment in trial of BMAC autologous cell composition to treat Congestive Heart Failure

Harvest Technologies Corp. announced today that the first twelve patients of its sixty patient Heart Failure trial have been enrolled at Medanta-the Medicity in Gurgaon INDIA.

21 Apr 2011

Amgen, UCB report positive results from AMG 785/CDP7851 comparative Phase 2 study for postmenopausal osteoporosis

Amgen and UCB announced today positive top-line results from their Phase 2 clinical study comparing sclerostin-antibody AMG 785/CDP7851 to placebo in postmenopausal women with low bone mineral density (BMD) for the treatment of postmenopausal osteoporosis (PMO).

21 Apr 2011

ARIAD executes three exclusive out-license agreements for ARGENT cell-signaling regulation technology

ARIAD Pharmaceuticals, Inc. today announced execution of three exclusive out-license agreements for separate aspects of its ARGENT™ cell-signaling regulation technology.

20 Apr 2011

Clontech releases iDimerize inducible dimerization systems

Clontech Laboratories, Inc., a wholly-owned subsidiary of Takara Bio Inc., today announced the release of the iDimerize inducible dimerization systems. Based on the widely used ARGENT™ technology developed by ARIAD Pharmaceuticals, Inc., the iDimerize systems enable precise, real-time control of protein-protein interactions using specific cell-permeable chemical ligands, called dimerizers.

20 Apr 2011

bluebird bio announces receipt of additional $30 million in financing

bluebird bio, an emerging leader in the development of innovative gene therapies for severe genetic disorders, today announced that the company has secured an additional $30 million in financing.

20 Apr 2011